[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd ADR (RHHBY)

Roche Holding Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 350,188,480
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,471 M
  • Annual Income, $ 15,546 M
  • EBIT $ 0 M
  • EBITDA $ 26,387 M
  • 60-Month Beta 0.50
  • Price/Sales 4.71
  • Price/Cash Flow 15.21
  • Price/Book 7.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.97 (1.78%)
  • Most Recent Dividend 0.972 on 03/13/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.1000 +8.44%
on 07/14/26
57.0000 -4.68%
on 07/29/26
+2.8800 (+5.80%)
since 06/30/26
3-Month
48.1000 +12.95%
on 06/02/26
57.0000 -4.68%
on 07/29/26
+3.3500 (+6.78%)
since 04/30/26
52-Week
37.5100 +44.84%
on 08/11/25
60.8500 -10.71%
on 02/24/26
+14.1700 (+35.62%)
since 07/30/25

Most Recent Stories

More News
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

INDIANAPOLIS , July 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas ...

ROG : 121.12 (+3.71%)
RHHBY : 54.3250 (-1.17%)
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges

INDIANAPOLIS , July 22, 2026 /PRNewswire/ -- (SIX: RO, ROP; OTCQX: RHHBY) As clinical laboratories face ongoing staffing shortages and increasingly complex workflows, Roche  will showcase integrated...

ROP : 390.90 (-4.21%)
RHHBY : 54.3250 (-1.17%)
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America

INDIANAPOLIS , July 20, 2026 /PRNewswire/ -- Roche  (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective...

ROP : 390.90 (-4.21%)
RHHBY : 54.3250 (-1.17%)
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

Priority review decision is based on Phase III MAJESTY results, where Gazyva achieved significantly higher complete remission rates at two years compared to tacrolimus ...

RHHBY : 54.3250 (-1.17%)
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

NVDA : 195.89 (+3.09%)
AAPL : 331.15 (-2.08%)
AVGO : 386.11 (+4.26%)
SAP : 181.03 (-2.67%)
JNJ : 255.95 (-3.61%)
RY : 209.57 (+1.51%)
NVS : 157.18 (-1.04%)
RHHBY : 54.3250 (-1.17%)
NSRGY : 101.8900 (+0.17%)
SBGSY : 64.7900 (+10.50%)
MSFT : 450.43 (+15.34%)
VIG : 239.47 (+0.38%)
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical...

RHHBY : 54.3250 (-1.17%)
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib...

RHHBY : 54.3250 (-1.17%)
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision)...

RHHBY : 54.3250 (-1.17%)
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

RXRX : 3.00 (+1.01%)
RHHBY : 54.3250 (-1.17%)
SNY : 41.95 (-6.47%)
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

QNTM : 2.83 (+1.77%)
QNTM.CN : 4.0000 (unch)
CLNN : 5.00 (+5.93%)
RHHBY : 54.3250 (-1.17%)
SNY : 41.95 (-6.47%)
BIIB : 205.19 (-1.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 58.7133
2nd Resistance Point 57.8567
1st Resistance Point 56.4133
Last Price 54.3250
1st Support Level 54.1133
2nd Support Level 53.2567
3rd Support Level 51.8133

See More

52-Week High 60.8500
Last Price 54.3250
Fibonacci 61.8% 51.9341
Fibonacci 50% 49.1800
Fibonacci 38.2% 46.4259
52-Week Low 37.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.